# Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangeme

Source: https://onco.cc/trials/nct02568267/  
OnCo record `nct02568267` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Entrectinib in colorectal cancer and melanoma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) is a phase 2 interventional study registered as NCT02568267 by Hoffmann-La Roche, with 534 participants enrolled, started 2015-11-19 and due to reach its primary completion in 2027-06-30. Interventions recorded: Entrectinib. Conditions listed: Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT02568267
- Phase: 2
- Setting: An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
- Sponsor: Hoffmann-La Roche
- Enrolled: 534

## Sources

- ClinicalTrials.gov NCT02568267: https://clinicaltrials.gov/study/NCT02568267

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Melanoma](https://onco.cc/cancers/melanoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Entrectinib](https://onco.cc/drugs/entrectinib/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct02568267.json